Design, synthesis, and evaluation of azepine-based cryptophycin mimetics

Tetrahedron

Volumn 59, Issue 35, 2003, Pages 6991-7009

  Smith III, Amos B ^a   Cho, Young Shin ^a   Pettit, G Robert ^b   Hirschmann, Ralph ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cryptophycin; Microtubule; Non peptide peptidomimetics

Indexed keywords

ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; CRYPTOPHYCIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; X RAY ANALYSIS;

ALGAE; CHLOROPHYTA; CYANOBACTERIA; UNCULTURED CYANOBACTERIUM;

EID: 0042158268     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(03)00857-3     Document Type: Article

References (78)

1. (a) Schwartz R.E., Hirsch C.F., Sesin D.F., Flor J.E., Chartrain M., Fromtling R.E., Harris G.H., Salvatore M.J., Liesch J.M., Yudin K. J. Ind. Microbiol. 5:1990;113-123.
2. (b) Hirsch, C. F.; Liesch, J. M.; Salvatore, M. J.; Schwartz, R. E.; Sesin, D. F. US Patent 4,949,835, 1990.
3. (a) Kobayashi M., Aoki S., Ohyabu N., Kurosu M., Wang W., Kitagawa I. Tetrahedron Lett. 35:1994;7969-7972.
4. (b) Kobayashi M., Kitagawa I. J. Nat. Toxins. 8:1999;249-258.
5. (a) Trimurtulu G., Ohtani I., Patterson G.M.L., Moore R.E., Corbett T.H., Valeriote F.A., Demchik L. J. Am. Chem. Soc. 116:1994;4729-4737.
6. (b) Golakoti T., Ogino J., Heltzel C.E., Le Husebo T., Jensen C.M., Larsen L.K., Patterson G.M.L., Moore R.E., Mooberry S.L., Corbett T.H., Valeriote F.A. J. Am. Chem. Soc. 117:1995;12030-12049.
7. Barrow R.A., Hemscheidt T., Liang J., Paik S., Moore R.E., Tius M.A. J. Am. Chem. Soc. 117:1995;2479-2490.
8. (a) Corbett T.H., Valeriote F.A., Demchik L., Lowichik N., Polin L., Panchapor C., Pugh S., White K., Kushner J., Rake J., Wentland M., Golakoti T., Hetzel C., Ogino J., Patterson G., Moore R. Invest. New Drugs. 15:1997;207-218.
9. (b) Moore R.E., Corbett T.H., Patterson G.M.L., Valeriote F.A. Curr. Pharm. Des. 2:1996;317-330.
10. (a) Trimurtulu G., Ohtani I., Patterson G.M.L., Moore R.E., Corbett T.H., Valeriote F.A., Demchik L. J. Am. Chem. Soc. 116:1994;4729-4737.
11. (b) Smith C.D., Zhang X., Mooberry S.L., Patterson G.M.L., Moore R.E. Cancer Res. 54:1994;3779-3784.
12. (c) Panda D., Himes R.H., Moore R.E., Wilson L., Jordan M.A. Biochemistry. 36:1997;12948-12953.
13. (a) Kerksiek K., Mejillano M.R., Schwartz R.E., Georg G.I., Himes R.H. FEBS Lett. 377:1995;59-61.
14. (b) Bai R.L., Schwartz R.E., Kepler J.A., Pettit G.R., Hamel E. Cancer Res. 56:1996;4398-4406.
15. (c) Mooberry S.L., Taoka C.R., Busquets L. Cancer Lett. 107:1996;53-57.
16. (d) Smith C.D., Zhang X. J. Biol. Chem. 271:1996;6192-6198.
17. (e) Mooberry S.L., Busquets L., Tien G. Int. J. Cancer. 73:1997;440-448.
18. (f) Bai R.L., Durso N.A., Sackett D.L., Hamel E. Biochemistry. 38:1999;14302-14310.
19. Gardinier K.M., Leahy J.W. J. Org. Chem. 62:1997;7098-7099.
20. (a) Norman B.H., Hemscheidt T., Schultz R.M., Andis S.L. J. Org. Chem. 63:1998;5288-5294.
21. (b) Liang J., Moher E.D., Moore R.E., Hoard D.W. J. Org. Chem. 65:2000;3143-3147.
22. (c) Panda D., DeLuca K., Williams D., Jordan M.A., Wilson L. Proc. Natl Acad. Sci. USA. 95:1998;9313-9318.
23. (a) Polin L., Jones J., White K., LoRusso P., Valeriote F., Moore R.E., Patterson G.M.L., Corbett T.H. Proc. Am. Assoc. Cancer Res. 37:1996;299. Abstract No. 2034.
24. (b) Corbett T.H., Valeriote F.A., Demchik L., Polin L., Panchapor C., Pugh S., White K., Knight J., Jones J. J. Exp. Therap. Oncol. 1:1996;95-108.
25. (c) Polin L., Valeriote F., White K., Panchapor C., Pugh S., Knight J., LoRusso P., Hussain M., Liversidge E., Peltier N., Golakoti T., Patterson G., Moore R., Corbett T.H. Invest. New Drugs. 15:1997;99-108.
26. (d) Georg G.I., Ali S.M., Stella V.J., Waugh W.N., Himes R.H. Bioorg. Med. Chem. Lett. 8:1998;1959-1962.
27. (a) Panda D., DeLuca K., Williams D., Jordan M.A., Wilson L. Proc. Natl Acad. Sci. USA. 95:1998;9313-9318.
28. (b) Corbett T., Valeriote F., Simpson C., Moore R., Tius M., Barrow R., Hemscheide T., Liang J., Paik S., Polin L., Pugh S., Kushner J., Harrison S., Shih J., Martinelli M. Proc. Am. Assoc. Cancer Res. 38:1997;225. Abstract No. 1515.
29. (c) Worzalla J.F., Cao J., Ehlhardt W.J., Harrison S.D., Law K.L., Martinelli M.J., Self T.D., Starling J.J., Shih C., Theobald K.S., Toth J.E., Zimmermann J.L., Corbett T.H. Proc. Am. Assoc. Cancer Res. 38:1997;225. Abstract No. 1516.
30. (d) Panda D., Ananthnarayan V., Larson G., Shih C., Jordan M.A., Wilson L. Biochemistry. 39:2000;14121-14127.
31. (e) Wagner M.M., Paul D.C., Shih C., Jordan M.A., Wilson L., Williams D.C. Cancer Chemother. Pharmacol. 43:1999;115-125
32. (f) Kessel D., Luo Y. Cancer Lett. 151:2000;25-29.
33. Kobayashi M., Kurosu M., Wang W., Kitagawa I. Chem. Pharm. Bull. 42:1994;2394-2396.
34. Eggen M., Georg G.I. Med. Res. Rev. 22:2002;85-101. and references therein.
35. For a preliminary account, see: Smith A.B., Cho Y.S., Zawacki L.E., Hirschmann R., Pettit G.R. Org. Lett. 3:2001;4063-4066.
36. (a) Farmer P.S. Ariens E.J. Drug Design. Vol. 10:1980;119 Academic, New York.
37. (b) Bélanger P.C., DuFresne C. Can. J. Chem. 64:1986;1514-1520.
38. Concurrent with the early Penn studies, Olson and co-workers at Hoffmann LaRoche reported a conceptually similar approach with the synthesis of a thyrotropin-releasing hormone mimic, which employed a cyclohexane scaffold, see Olson G.L., Cheung H.-C., Foss M.E., Hahn M., Madison V.S., Cook C.M., Speinwall J., Vincent G. Proc. Biotechnol. (USA). 1989;Conference Management Corporation, Norwalk. pS 348.
39. (a) Nicolaou, K. C.; Salvino, J. M.; Raynor, K.; Pietranico, S.; Freidinger, R. M.; Reisine, T.; Hirschmann, R. Abstracts of the American Chemical Society 198: 119-MBTD SEP 10, 1989.
40. (b) Hirschmann R., Nicolaou K.C., Pietranico S., Salvino J., Leahy E.M., Sprengeler P.A., Furst G., Smith A.B. III, Strader C.D., Cascieri M.A., Candelore M.R., Donaldson C., Vale W., Maechler L. J. Am. Chem. Soc. 114:1992;9217-9218.
41. (c) Smith A.B. III, Keenan T.P., Holcomb R.C., Sprengler P.A., Guzman M.C., Wood J.L., Carroll P.J., Hirschmann R. J. Am. Chem. Soc. 114:1992;10672-10674.
42. (a) Hirschmann R., Nicolaou K.C., Pietranico S., Leahy E.M., Salvino J., Arison B., Cichy M.A., Spoors P.G., Shakespeare W.C., Sprengeler P.A., Hamley P., Smith A.B. III, Reisine T., Raynor K., Maechler L., Donaldson C., Vale W., Freidinger R.M., Cascieri M.R., Strader C.D. J. Am. Chem. Soc. 115:1993;12550-12568.
43. (b) Liu J., Underwood D.J., Cascieri M.A., Rohrer S.P., Cantin L.D., Chicchi G., Smith A.B. III, Hirschmann R. J. Med. Chem. 43:2000;3827-3831.
44. (c) Hirschmann R., Hynes J., Cichy-Knight M.A., van Rijn R.D., Sprengeler P.A., Spoors P.G., Shakespeare W.C., Pietranico-Cole S., Barbosa J., Liu J., Yao W.Q., Rohrer S., Smith A.B. III. J. Med. Chem. 41:1998;1382-1391.
45. (d) Smith A.B. III, Hirschmann R., Pasternak A., Akaishi R., Guzman M.C., Jones D.R., Keenan T.P., Sprengeler P.A., Darke P.L., Emini E.A., Holloway M.K., Schleif W.A. J. Med. Chem. 37:1994;215-218.
46. (e) Smith A.B. III, Hirschmann R., Pasternak A., Yao W.Q., Sprengeler P.A., Holloway M.K., Kuo L.C., Chen Z.G., Darke P.L., Schleif W.A. J. Med. Chem. 40:1997;2440-2444.
47. (f) Murphy P.V., O'Brian J.L., Gorey-Feret L.J., Smith A.B. III. Bioorg. Med. Chem. Lett. 12:2002;1763-1766.
48. (g) Murphy P.V., O'Brian J.L., Gorey-Feret L.J., Smith A.B. III. Tetrahedron. 59:2003;2259-2271.
49. (h) Smith A.B. III, Nittoli T., Sprengeler P.A., Duan J.J.W., Liu R.Q., Hirschmann R.F. Org. Lett. 2:2000;3809-3812
50. (i) Smith A.B. III, Benowitz A.B., Sprengeler P.A., Barbosa J., Guzman M.C., Hirschmann R., Schweiger E.J., Bolin D.R., Nagy Z., Campbell R.M., Cox D.C., Olson G.L. J. Am. Chem. Soc. 121:1999;9286-9298.
51. (a) Evans B.E., Rittle K.E., Bock M.G., Dipardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Loti V.J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., Hirshfield. J. Med. Chem. 31:1988;2235-2246.
52. (b) Patchett A.A., Nargund R.P. Ann. Rep. Med. Chem. 35:2000;289-298.
53. (c) Horton D.A., Bourne G.T., Smythe M.L. Chem. Rev. 103:2003;893-930.
54. Specific details of these studies are outlined in the Experimental Section.
55. Campbell A.L., Pilipauskas D.R., Khanna I.K., Rhodes R.A. Tetrahedron Lett. 28:1987;2331-2334.
56. (a) Grubbs R.H., Miller S.J., Fu G.C. Acc. Chem. Res. 28:1995;446-452.
57. (b) Miller S.J., Blackwell H.E., Grubbs R.H. J. Am. Chem. Soc. 118:1996;9606-9614.
58. (c) Dias E.L., Nguyen S.T., Grubbs R.H. J. Am. Chem. Soc. 119:1997;3887-3897.
59. (a) Martinez L.E., Leighton J.L., Carsten D.H., Jacobsen E.N. J. Am. Chem. Soc. 117:1995;5897-5898.
60. (b) Leighton J.L., Jacobsen E.N. J. Org. Chem. 61:1996;389-390.
61. (c) Schaus S.E., Larrow J.F., Jacobsen E.N. J. Org. Chem. 62:1997;4197-4199.
62. Chakraborty T.K., Thippeswamy D., Suresh V.R., Jayaprakash S. Chem. Lett. 1997;563-564.
63. (a) Borch R.F., Bernstei M.D., Durst H.D. J. Am. Chem. Soc. 93:1971;2897-2904.
64. (b) Borch R.F., Hassid A.I. J. Org. Chem. 37:1972;1673-1674.
65. (c) Lane C.F. Synthesis. 1975;135-146.
66. Maryanoff B.E., Reitz A.B. Chem. Rev. 89:1989;863-927.
67. (a) Smith A.B. III, Rano T.A., Chida N., Sulikowski G.A., Wood J.L. J. Am. Chem. Soc. 114:1992;8008-8022.
68. (b) Kim G., Chumoyer M.Y., Danishefsky S.J., Schulte G.K. J. Am. Chem. Soc. 115:1993;30-39.
69. Chen Y.L., Liston D., Nielsen J., Chapin D., Dunaiskis A., Hedberg K., Ives J., Johnson J., Jones S. J. Med. Chem. 37:1994;1996-2000.
70. Ferrer M., Sanchezbaeza F., Messeguer A., Diez A., Rubiralta M. Chem. Commun. 1995;293-294.
71. The stereochemistry of epoxides (-)-31 and (-)-32 was determined via hydrogenolysis to the corresponding homobenzylic alcohols, which permitted correlation to compounds previously synthesized in our group.
72. For the protocols used for the bioassays in the Pettit laboratory, see: Nogawa T., Kamano Y., Yamashita A., Pettit G.R. J. Nat. Prod. 64:2001;1148-1152.
73. 50 value of 0.037 nM (0.000025 μg/mL) against MCF-7 breast-adenocarcinoma (see Ref. 11e).
74. Kolb H.C., Sharpless K.B. Tetrahedron. 48:1992;10515-10530.
75. Sharpless K.B., Amberg W., Bennani Y.L., Crispino G.A., Hartung J., Jeong K.S., Kwong H.L., Morikawa K., Wang Z.M., Xu D.Q., Zhang X.L. J. Org. Chem. 57:1992;2768-2771.
76. At that time, epoxide opening with alcohol in the presence of Jacobsen catalyst (S,S)-15 had not been reported to the best of our knowledge.
77. Horning E.C. Organic Syntheses. Collect. Vol. III:1943;Wiley, New York. p 267.
78. Majer P., Randad R.S. J. Org. Chem. 59:1994;1937-1938.